HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pan-Chyr Yang Selected Research

cryptopleurine

8/2012Antitumor agents 295. E-ring hydroxylated antofine and cryptopleurine analogues as antiproliferative agents: design, synthesis, and mechanistic studies.
7/2011Antitumor agents 288: design, synthesis, SAR, and biological studies of novel heteroatom-incorporated antofine and cryptopleurine analogues as potent and selective antitumor agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pan-Chyr Yang Research Topics

Disease

137Neoplasms (Cancer)
11/2021 - 02/2002
87Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2021 - 02/2002
85Lung Neoplasms (Lung Cancer)
01/2022 - 11/2002
66Adenocarcinoma of Lung
01/2021 - 11/2002
40Neoplasm Metastasis (Metastasis)
06/2022 - 11/2002
21Adenocarcinoma
10/2017 - 11/2002
19Carcinogenesis
01/2022 - 11/2002
11Infections
11/2021 - 01/2002
11Tuberculosis (Tuberculoses)
01/2016 - 09/2004
9Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2018 - 07/2005
9Hypoxia (Hypoxemia)
11/2018 - 08/2005
8Pneumonia (Pneumonitis)
01/2014 - 06/2004
7Severe Acute Respiratory Syndrome
01/2022 - 10/2004
7Disease Progression
01/2021 - 10/2004
7Lung Injury
01/2019 - 11/2006
7Pneumothorax
04/2018 - 02/2002
7Carcinoma (Carcinomatosis)
06/2015 - 07/2003
7Lymphatic Metastasis
08/2014 - 11/2002
7Chronic Obstructive Pulmonary Disease (COPD)
01/2014 - 09/2006
6Inflammation (Inflammations)
06/2015 - 08/2005
5Hemorrhage
04/2018 - 10/2004
4Lung Diseases (Lung Disease)
08/2022 - 04/2003
4Respiratory Insufficiency (Respiratory Failure)
06/2022 - 12/2003
4Melanoma (Melanoma, Malignant)
12/2020 - 08/2015
4Malignant Pleural Effusion
07/2017 - 04/2011
4Lymphoma (Lymphomas)
04/2016 - 01/2012
4Sarcoma (Soft Tissue Sarcoma)
04/2016 - 05/2014
4Lymphopenia (Lymphocytopenia)
06/2015 - 05/2004
4Sepsis (Septicemia)
06/2015 - 08/2005
4Breast Neoplasms (Breast Cancer)
04/2013 - 06/2003
4Critical Illness (Critically Ill)
08/2010 - 08/2004
3Brain Neoplasms (Brain Tumor)
02/2018 - 01/2008
3Hepatocellular Carcinoma (Hepatoma)
01/2014 - 02/2003
3Pulmonary Tuberculosis
03/2013 - 01/2010
3Pleural Effusion (Pleural Effusions)
05/2012 - 04/2005

Drug/Important Bio-Agent (IBA)

55ErbB Receptors (EGF Receptor)IBA
10/2020 - 02/2006
42Proteins (Proteins, Gene)FDA Link
11/2021 - 11/2002
30Tyrosine Kinase InhibitorsIBA
01/2021 - 12/2008
29Gefitinib (Iressa)FDA Link
11/2019 - 06/2005
18Pharmaceutical PreparationsIBA
01/2021 - 09/2004
15Biomarkers (Surrogate Marker)IBA
08/2021 - 04/2008
15MicroRNAs (MicroRNA)IBA
01/2017 - 07/2006
14Messenger RNA (mRNA)IBA
06/2015 - 02/2002
13CytokinesIBA
01/2021 - 10/2004
13DNA (Deoxyribonucleic Acid)IBA
01/2018 - 12/2006
10AntigensIBA
01/2020 - 07/2003
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2016 - 02/2002
10Interleukin-8 (Interleukin 8)IBA
06/2015 - 02/2002
9Small Interfering RNA (siRNA)IBA
01/2022 - 12/2006
9Pemetrexed (MTA)FDA Link
11/2020 - 02/2011
8Biological ProductsIBA
07/2020 - 01/2005
8ParaffinIBA
03/2017 - 06/2011
8Anti-Bacterial Agents (Antibiotics)IBA
01/2013 - 09/2003
7EnzymesIBA
11/2021 - 10/2005
7Interleukin-6 (Interleukin 6)IBA
01/2019 - 02/2005
7Protein Isoforms (Isoforms)IBA
03/2016 - 01/2004
7NF-kappa B (NF-kB)IBA
01/2013 - 02/2003
6Phosphotransferases (Kinase)IBA
01/2021 - 12/2007
6LigandsIBA
01/2021 - 01/2005
6Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2015 - 03/2004
5Cadherins (E-Cadherin)IBA
01/2019 - 06/2005
5RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
07/2017 - 02/2005
5AntibodiesIBA
01/2016 - 06/2005
5CurcuminIBA
04/2015 - 01/2004
5C-Reactive ProteinIBA
12/2012 - 12/2003
5collapsin response mediator protein-1IBA
01/2012 - 01/2003
5InterleukinsIBA
10/2005 - 03/2004
4VaccinesIBA
01/2022 - 01/2014
4Cisplatin (Platino)FDA LinkGeneric
04/2020 - 04/2007
4ChemokinesIBA
01/2019 - 11/2006
4PlatinumIBA
03/2017 - 11/2008
4Anaplastic Lymphoma KinaseIBA
01/2017 - 05/2014
4SmokeIBA
02/2016 - 08/2010
4CateninsIBA
08/2014 - 08/2012
4GemcitabineFDA Link
08/2012 - 01/2008
3Peptides (Polypeptides)IBA
04/2021 - 08/2007
3Immune Checkpoint InhibitorsIBA
01/2021 - 01/2020
3Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2020 - 01/2016
3Thymidylate SynthaseIBA
09/2017 - 10/2011
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2016 - 05/2011
3AfatinibIBA
03/2016 - 05/2012
3CarcinogensIBA
02/2016 - 08/2010
3Antiviral Agents (Antivirals)IBA
01/2016 - 01/2014
3Membrane Proteins (Integral Membrane Proteins)IBA
12/2015 - 07/2003
3Minocycline (Cyclops)FDA LinkGeneric
07/2014 - 11/2008
3IntegrinsIBA
01/2013 - 03/2004
3Bevacizumab (Avastin)FDA Link
08/2012 - 02/2011
3Interferon-gamma (Interferon, gamma)IBA
03/2012 - 11/2006
3pyrrolidine dithiocarbamic acidIBA
02/2012 - 02/2003
3Erlotinib Hydrochloride (CP 358,774)FDA Link
05/2011 - 12/2007

Therapy/Procedure

58Therapeutics
06/2022 - 04/2003
25Drug Therapy (Chemotherapy)
04/2020 - 12/2002
8Immunotherapy
06/2022 - 05/2014
7Pleurodesis
07/2014 - 02/2002
6Radiotherapy
07/2020 - 01/2008
5Chest Tubes (Chest Tube)
04/2018 - 08/2002
5Artificial Respiration (Mechanical Ventilation)
01/2009 - 04/2003
4Aftercare (After-Treatment)
04/2020 - 03/2006
4Hormone Replacement Therapy (Therapy, Hormone Replacement)
10/2015 - 10/2007
3Adjuvant Chemotherapy
08/2014 - 04/2013